{"id":"infliximab-qbtx","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT04305145","NCT05034536","NCT05660746","NCT06646016"],"aliases":[],"company":"PFIZER INC","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=INFLIXIMAB-QBTX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:46:36.103328+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:46:42.563147+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=INFLIXIMAB-QBTX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:46:43.341091+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: TNF-alpha inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:46:44.046858+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201581/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:46:43.963074+00:00"}},"allNames":"ixifi","offLabel":[],"timeline":[],"brandName":"IXIFI","ecosystem":[],"mechanism":{"target":"Tumor necrosis factor","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:46:45.812359+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"INFLIXIMAB-QBTX","indications":{"approved":[{"name":"Ankylosing spondylitis","diseaseId":"ankylosing-spondylitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Behcet's disease","diseaseId":"behcet's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Crohn's disease","diseaseId":"crohn's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Erythrodermic psoriasis","diseaseId":"erythrodermic-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Plaque psoriasis","diseaseId":"plaque-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriasis with arthropathy","diseaseId":"psoriasis-with-arthropathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pustular psoriasis","diseaseId":"pustular-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ulcerative colitis","diseaseId":"ulcerative-colitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"PFIZER INC","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04305145","phase":"Phase 2","title":"Phase II Study of Infliximab for the Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":42,"indication":"Melanoma Stage III, Melanoma Stage IV","completionDate":"2030-06-30"},{"nctId":"NCT05034536","phase":"Phase 2","title":"A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":36,"indication":"Metastatic Melanoma","completionDate":"2027-12-31"},{"nctId":"NCT05660746","phase":"Phase 2","title":"Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","isPivotal":true,"enrollment":180,"indication":"Crohn Disease","completionDate":"2027-03-31"},{"nctId":"NCT06646016","phase":"Phase 2","title":"EPIC - A Phase 2, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) in ","status":"WITHDRAWN","sponsor":"Therakos LLC","isPivotal":false,"enrollment":0,"indication":"Immune-related Colitis","completionDate":"2027-02-19"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"INJECTION","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL1201581"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"PFIZER INC","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"IXIFI is a drug that targets tumor necrosis factor, specifically inhibiting TNF-alpha. It is being studied in clinical trials for various conditions, including immune-related colitis, melanoma, and skin cancer, and is administered as an antibody.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-12-13T00:00:00.000Z","mah":"PFIZER INC","brand_name_local":"IXIFI","application_number":"BLA761072"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:46:45.812359+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}